Evidence map›Paper›PMID 39212853›Full record

ArticleInfectious diseases and therapy2024

Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.

Colleen S Kraft, Matthew Sims, Michael Silverman, Thomas J Louie, Paul Feuerstadt, Edward S Huang, Sahil Khanna, Charles S Berenson, Elaine E L Wang, Stuart H Cohen and 16 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Colleen S KraftDepartment of Pathology and Laboratory Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA, USA.
Matthew SimsSection of Infectious Diseases and International Medicine, Department of Internal Medicine, Beaumont Royal Oak, Royal Oak, MI, USA.
Michael SilvermanWestern University, London, ON, Canada.
Thomas J LouieCumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Paul FeuerstadtDivision of Digestive Disease, Yale University School of Medicine, New Haven, CT, USA.
Edward S HuangDepartment of Gastroenterology, Palo Alto Medical Foundation, Sutter Health, Mountain View, CA, USA.
Sahil KhannaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Charles S BerensonUniversity at Buffalo, VA Western New York Healthcare System, Buffalo, NY, USA.
Elaine E L WangSeres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA.
Stuart H CohenUniversity of California Davis Health, Sacramento, CA, USA.
Louis KormanGastroenterology and Hepatology, Chevy Chase Clinical Research, Chevy Chase, MD, USA.
Christine LeeIsland Medical Program, University of British Columbia and University of Victoria, Vancouver, BC, Canada.
Colleen R KellyDivision of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.
Alberto OdioAdventist Health, Simi Valley, CA, USA.
Paul P CookBrody School of Medicine at East, Carolina University, Greenville, NC, USA.
Bret LashnerCleveland Clinic, Cleveland, OH, USA.
Mayur RameshDivision of Infectious Diseases, Henry Ford Health, Detroit, MI, USA.
Princy KumarDivision of Infectious Diseases and Tropical Medicine, Georgetown University Medical Center, Washington, DC, USA.
Ananya DeSeres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA.
Asli MemisogluSeres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA.
David A LombardiSeres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA.
Brooke R HassonSeres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA. bhasson@serestherapeutics.com.ORCID http://orcid.org/0009-0000-2991-0567
Barbara H McGovernSeres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA.
Lisa von MoltkeSeres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA.
Darrell S PardiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
ECOSPOR III and ECOSPOR IV investigators

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39212853
PMCPMC11416435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.